A leading specialty hospital has demonstrated that bone marrow stem cells can cure blood disorders like leukemia, thalassemia and aplastic anemia, a bone marrow failure.
“Bone marrow transplant has emerged as an effective cure for cancerous and genetic blood diseases through transfusion of its stem cells from a healthy donor to an affected patient,” Narayana Health City consultant hematologist Sharat Damodar told reporters here Tuesday.
The corporate hospital in the city’s southern suburb claims to have performed about 300 bone marrow transplants with over 80 per cent success rate.
Bone marrow can be collected from a related donor (siblings), matched unrelated donor
Image via Wikipedia
For patients who suffer a major heart attack, get treatment at the hospital but are left with a damaged heart, Dr. Roger Gammon of the Heart Hospital of Austin is testing a new process to reverse that damage.
Just as a Houston hospital is investigating stem cells to repair the brains of stroke patients (see yesterday’s blog), the Heart Hospital is trying out a new stem cell therapy to fix the hearts of patients who suffered their first attack.
It is one of the nation’s first hospitals to test the new therapy.
Gammon, an interventional cardiologist, is leading the clinical
Italy is ranked among the top countries in Europe for the number of bone marrow transplants performed. This is one of the elements that emerged on the first day of the 3rd GITMO conference (Italian group for bone marrow transplants), which began today in Florence.
Italy plays a leading role for bone marrow transplants, said a statement, demonstrated by the fact that our country is one of the top contributors to the number of transplants performed in Europe. The European Bone Marrow Transplant Group (EMBT) collects and stores data regarding transplants performed in various countries, and Italy is
Image via Wikipedia
Western Pennsylvania Cancer Institute’s Dr. Entezam Sahovic: We are hopeful that this new technology will enable us to help more patients in need of transplants.
A joint venture between Gamida Cell and Teva Pharmaceutical Industries Ltd. will carry out a study at Western Pennsylvania Hospital (WPH). WPH is currently enrolling patients for the study.
The ExCell study will assess the safety and efficacy of StemEx as a treatment for hematological malignancies, including leukemia and lymphoma, in a single arm, global, pivotal registration study.
StemEx is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood
A 41-site clinical trial, testing the restorative effect that adult bone marrow stem cells have on damaged or injured myocardium in heart attack patients, is being led at Wake Forest Baptist by Sanjay Gandhi, MD.
Phase I of the research study found that stem cells derived from bone marrow (mesenchymal stem cells) were safe for patients and may have the ability to limit scar formation, improve heart function and preserve tissue following a first heart attack.
Phase I was a multicenter study of 53 patients which demonstrated that the treatment was safe in adults, and those patients given this